![](https://webarchive.library.unt.edu/eot2008/20090201132613im_/http://www.cancer.gov/images/spacer.gif) |
|
Ovarian Cancer Trial Results
1. Ultrasound Expertise Important in the Diagnosis of Ovarian Cancer (Posted: 02/25/2008) - Improving the quality of diagnostic ultrasound scans could significantly reduce unnecessary surgeries in women with suspected ovarian cancer who, in fact, have benign disease, according to the February 2008 issue of the Lancet Oncology.
![](https://webarchive.library.unt.edu/eot2008/20090201132613im_/http://www.cancer.gov/images/spacer.gif)
2. Impact of Intraperitoneal Chemotherapy on Quality of Life During Ovarian Cancer Treatment (Posted: 02/14/2007) - Women with ovarian cancer treated with intraperitoneal (IP)chemotherapy reported more side effects and a lower quality of life during their treatment compared to women receiving intravenous chemotherapy. However, at the end of one year, only neurological symptoms remained worse for the IP group, according to the Feb. 1, 2007, Journal of Clinical Oncology.
![](https://webarchive.library.unt.edu/eot2008/20090201132613im_/http://www.cancer.gov/images/spacer.gif)
3. Review Confirms Effectiveness of Intraperitoneal Chemotherapy for Advanced Ovarian Cancer (Posted: 12/18/2006) - Combined data from 60 randomized clinical trials of advanced ovarian cancer showed that multidrug chemotherapy using a platinum-based drug and a taxane-based drug delivered directly into the abdomen (intraperitoneal chemotherapy) can help women survive a median of 5.5 years, according to the Nov. 15, 2006, Journal of the National Cancer Institute.
![](https://webarchive.library.unt.edu/eot2008/20090201132613im_/http://www.cancer.gov/images/spacer.gif)
4. Preventive Surgery Can Reduce Cancer Risk in Women with BRCA Gene Mutations (Posted: 05/28/2002, Updated: 10/04/2006) - Two separate studies in the May 23, 2002, issue of the New England Journal of Medicine support the practice of recommending preventive surgery in women with a genetic mutation that puts them at high risk of developing breast and gynecologic cancers.
![](https://webarchive.library.unt.edu/eot2008/20090201132613im_/http://www.cancer.gov/images/spacer.gif)
5. Gemcitabine Plus Carboplatin Benefits Women with Recurrent Ovarian Cancer (Posted: 09/27/2006) - A phase III randomized trial has shown a statistically significant improvement in progression-free survival for women with platinum-sensitive recurrent ovarian cancer given gemcitabine with carboplatin compared with carboplatin alone, according to a report published online Sept. 18, 2006, by the Journal of Clinical Oncology.
1 2 3 Next > |
|
![](https://webarchive.library.unt.edu/eot2008/20090201132613im_/http://www.cancer.gov/images/spacer.gif) |